The apparently very short time interval between NOX reporting the preliminary results for treatment of pancreatic cancer and FDA Orphan drug status is remarkable. Looks like the FDA sees this treatment as a potential significant breakthrough and have wasted no time in granting the Orphan Status
Ann: US FDA grants Orphan Drug Designation for CRO-67, page-2
Add NOX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
11.0¢ |
Change
0.014(14.6%) |
Mkt cap ! $32.14M | |||
| Open | High | Low | Value | Volume |
| 9.2¢ | 11.5¢ | 9.2¢ | $53.30K | 518.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 48681 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.0¢ | 74195 | 4 |
View Market Depth
| Last trade - 15.45pm 23/08/2024 (20 minute delay) ? |
| NOX (ASX) Chart |